Lars Fruergaard Jørgensen, CEO of Novo Nordisk, dives into the pressing issue of obesity as a complex health crisis. He shares insights on the company's innovative GLP-1 medication, addressing the major challenges of accessibility in Europe and the U.S. Jørgensen emphasizes the significance of purpose in the pharmaceutical industry and reflects on grounded leadership principles. The discussion also touches on navigating cultural differences in global teams and the value of non-linear career paths for fostering a sustainable work-life balance.

Novo Nordisk CEO discusses scaling up production of weight-loss drug Wegovy with Bloomberg journalists. Topics include manufacturing capacity, unit costs, pricing strategies in drug production, long-term use of weight loss drugs, administration routes, and personalized medicine.